FOR THE RECORD: Los Angeles Backs Down, Repeals Controversial Ordinance Targeting NRA

FOR THE RECORD

NRA LEGAL FACTS

Los Angeles Backs Down, Repeals Controversial Ordinance Targeting NRA

City is the Latest Governmental Body to Face Legal Reckoning Over Unlawful Attack

https://www.nralegalfacts.org/los-angeles-ordinance-media-advisor

January 21, 2020 — The Los Angeles City Council today voted to formally repeal a controversial city ordinance requiring contractors seeking to do business with the city to disclose ties to the National Rifle Association (NRA). The decision is another legal victory for the Association, which argued that the ordinance violated its First Amendment right to free speech and won an injunction blocking the law.

“The same city officials who vowed to defend this ordinance are on the run,” said Jason Ouimet, executive director of NRA’s Institute for Legislative Action. “In addition to the NRA members they wronged, city officials must now answer to voters and taxpayers for their failed experiment, and explain why they recklessly subjected the city to legal and financial exposure.”

Initially approved on Feb. 12, 2019, Ordinance No. 186000 took effect on April 1, 2019. The NRA filed suit against the city on April 24, 2019. The NRA argued that the ordinance would unjustly cut off “revenue streams necessary for the NRA to continue engaging in protected speech and association” by discouraging membership and stigmatizing business relationships and sponsorships.

The Court agreed. On Dec. 11, 2019, U.S. District Court Judge Stephen V. Wilson granted a preliminary injunction blocking enforcement of the ordinance, stating the NRA was likely to show the law violated its rights and would cause irreparable harm.

Despite the City Council’s decision to repeal the ordinance, the NRA intends to continue to pursue all available remedies.

“Facing a trial where they’ll have to account for the unconstitutional ordinance, city officials are trying to mitigate the consequences of their illegal misbehavior,” says Chuck Michel, California counsel to the NRA. “This is another decisive victory for the NRA, which stood and fought for its members’ rights.”

The legal victory in Los Angeles in the latest positive legal development for the NRA. In the face of a lawsuit by the NRA, on Sept. 23, 2019, San Francisco Mayor London Breed admitted that an ordinance that called for city agencies to limit relationships with companies that do business with the NRA was non-binding.

On May 11, 2018, the NRA filed a lawsuit against New York Gov. Andrew Cuomo and New York state regulators over a “blacklisting campaign” that seeks to intimidate the NRA’s potential business partners. That case survived a motion to dismiss and is moving forward. The case has garnered support from constitutional scholars and leading advocacy groups, including the ACLU.

Speaking about such First Amendment attacks on the NRA from governmental bodies, William A. Brewer III, outside counsel to the NRA, said, “Coast to coast, the Association has demonstrated its resolve to hold government actors accountable for their attempts to transgress against the rights of NRA members. The NRA will never stop defending its members and the freedoms they hold so dear.”

What in the World Are They Spraying? (Full Length HD Version)

What in the World Are They Spraying? (Full Length HD Version)

Aug 5, 2011

British Scientists May Have Found Cure For Cancer. By Accident.

British Scientists May Have Found Cure For Cancer. By Accident.

January 22nd, 2020

By  Hank Berrien

DailyWire.com

https://www.dailywire.com/news/british-scientist-may-have-found-cure-for-cancer-by-accident?itm_source=parsely-api?utm_source=cnemail&utm_medium=email&utm_content=012320-news&utm_campaign=position1

British scientists may have discovered a cure for cancer — by accident.

As The Telegraph reports, “Researchers at Cardiff University were analyzing blood from a bank in Wales, looking for immune cells that could fight bacteria, when they found an entirely new type of T-cell. That new immune cell carries a never-before-seen receptor which acts like a grappling hook, latching on to most human cancers, while ignoring healthy cells.”

What makes this new discovery so exciting is that prior therapies, referred to as CAR-T and TCR-T therapies, which use immune cells to attach to HLA molecules on cancer cells’ surface, fight cancer but are incapable of fighting solid tumors. As The Telegraph points out, HLA molecules vary in people, but the new therapy attaches to a molecule called MR1, which does not vary in humans, which gives it the chance of fighting most cancers and additionally means people could share the treatment, allowing banks of the cells to be stored and thus be offered quickly to people suffering from the disease.

Immune cells from the new treatment have killed lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical cancer cells. The study stated:

Human leukocyte antigen (HLA)-independent, T cell-mediated targeting of cancer cells would allow immune destruction of malignancies in all individuals. Here, we use genome-wide CRISPR-Cas9 screening to establish that a T cell receptor recognized and killed most human cancer types via the monomorphic MHC class-I related protein, MR1, while remaining inert to noncancerous cells … These finding offer opportunities for HLA-independent, pan-cancer, pan-population immunotherapies.

The study concluded, “In summary, we describe a TCR that exhibits pan-cancer recognition via the variant MR1 molecule, and, by equipping patients with melanoma T cells that lacked detectable cancer reactivity with the MC.7 G5 TCR, we rendered the T-cells capable of killing autologous melanoma.”

Professor Andrew Sewell, lead author on the study, enthused to the Telegraph, “This was a serendipitous finding, nobody knew this cell existed. Our finding raises the prospect of a ‘one-size-fits-all’ cancer treatment, a single type of T-cell that could be capable of destroying many different types of cancers across the population. Previously nobody believed this could be possible.”

Astonishingly, T-cells of skin cancer patients altered by the treatment were apparently capable of killing the patient’s cancer cells and other patients’ cancer cells as well. The team of researchers posited that trials on terminally ill patients could conceivably start in November.

Professor Oliver Ottmann, Cardiff University’s Head of Haematology, stated: “This new type of T-cell therapy has enormous potential to overcome current limitations of CAR-T, which has been struggling to identify suitable and safe targets for more than a few cancer types.”

Professor Awen Gallimore of Cardiff University’s division of infection and immunity and cancer immunology lead for the Wales Research Centre, added, “If this transformative new finding holds up, it will lay the foundation for a ‘universal’ T-cell medicine, mitigating against the tremendous costs associated with the identification, generation and manufacture of personalized T-cells.  This is truly exciting and potentially a great step forward for the accessibility of cancer immunotherapy.”

The research was published here.